Last updated: October 31, 2026
TachoSil is a fibrin sealant patch used to control bleeding during surgery. Its active components are human fibrinogen and human thrombin, which are applied to a collagen sponge. Takeda commercialized TachoSil for many years before selling the product to Corza Medical in 2021. Public companies do not separately report TachoSil revenue, so its precise sales trajectory and current market share cannot be verified from audited financial statements. [1][2]
The product has no conventional generic or biosimilar threat comparable to a small-molecule medicine or injectable monoclonal antibody. Its main risks are hospital-budget pressure, competing hemostatic technologies, procedure-volume changes, and substitution by other fibrin sealants, oxidized cellulose products, gelatin matrices, flowable agents, and electrosurgical devices.
What is TachoSil and how does it work?
TachoSil is an absorbable surgical patch consisting of a collagen sponge coated with human fibrinogen and human thrombin. When the coated yellow side contacts blood or other fluid, the fibrinogen is converted into fibrin. The resulting fibrin clot adheres to the tissue and supports local hemostasis.
TachoSil is used as an adjunct when conventional surgical techniques are insufficient or impractical. Its principal commercial value is procedural convenience: the surgeon applies a ready-to-use patch directly to a bleeding surface rather than mixing components or delivering a liquid sealant.
What are TachoSil’s principal clinical uses?
TachoSil has been used in procedures including:
- Cardiovascular surgery
- Liver surgery
- Thoracic surgery
- General soft-tissue surgery
- Vascular and transplant procedures
- Control of diffuse or surface bleeding
The product is not a systemic therapy. Demand is linked to surgical case volume, adoption by hospitals and surgeons, local reimbursement, and the preference for ready-to-use hemostatic products.
Who owns TachoSil and how has commercialization changed?
Takeda inherited TachoSil through its acquisition of Nycomed in 2011. In 2021, Takeda agreed to sell TachoSil to Corza Medical, a privately held surgical products company. The transaction formed part of Takeda’s broader divestiture program to reduce non-core assets and focus on its principal therapeutic areas. [1]
| Period |
Commercial owner |
Strategic position |
| Before 2011 |
Nycomed |
Originator commercialization |
| 2011-2021 |
Takeda |
Non-core surgical product within a diversified pharmaceutical portfolio |
| From 2021 |
Corza Medical |
Core surgical-hemostasis product within a specialty medical-device portfolio |
The change in ownership matters because TachoSil is more commercially aligned with Corza’s surgical portfolio than with Takeda’s current focus on gastroenterology, rare diseases, neuroscience and plasma-derived therapies.
What is TachoSil’s financial trajectory?
TachoSil revenue is not separately disclosed in Takeda’s publicly reported product tables, and Corza Medical is privately held. No audited, product-level revenue series is therefore available.
What can be established from public financial records?
Takeda classified TachoSil as a divestible or non-core asset rather than as a major growth driver in its pharmaceutical portfolio. The company disclosed the divestiture transaction but did not provide a standalone historical revenue, operating-margin, or unit-volume series for TachoSil. [1]
Corza has not published product-level sales for TachoSil. Its financial position is therefore best assessed through commercial indicators rather than reported earnings:
| Financial indicator |
Public status |
| Annual TachoSil revenue |
Not separately disclosed |
| TachoSil unit volume |
Not disclosed |
| Product gross margin |
Not disclosed |
| Current market share |
Not publicly verified |
| Acquisition purchase price |
Reported by Takeda as part of transaction disclosures, but product-level valuation was not isolated |
| Corza Medical revenue |
Not publicly reported in a detailed product-level filing |
The absence of public revenue data prevents a defensible calculation of annual growth, compound annual growth rate, or current revenue exposure.
What are the main revenue drivers?
TachoSil revenue is likely driven by five variables:
- Procedure volume in cardiovascular, thoracic, liver and general surgery.
- Use per procedure, including whether surgeons apply one patch or multiple patches.
- Hospital formulary placement.
- Competitive pricing and contracting.
- Product conversion from liquid, powder, mesh or mechanical hemostatic products.
Demand is relatively resilient when TachoSil is used in complex surgery, but hospitals can switch among several hemostatic technologies. The product therefore has clinical differentiation without having an exclusive position in surgical bleeding control.
How large is the competitive market for surgical hemostasis?
TachoSil competes in a broad surgical-hemostasis market rather than a narrowly defined drug class. Relevant alternatives include:
| Competitor or category |
Company examples |
Delivery format |
Competitive relevance |
| Fibrin sealants |
Tisseel, Vistaseal, Evicel |
Liquid |
Strong substitute where surgeons want broad surface coverage or injectable delivery |
| Fibrin patch products |
Evarrest and related products |
Patch |
Closest functional comparison |
| Oxidized regenerated cellulose |
Surgicel |
Sheet, fabric, powder |
Lower-cost and widely stocked mechanical/chemical alternative |
| Gelatin matrices |
Floseal, Surgiflo |
Flowable matrix |
Useful in irregular bleeding sites |
| Microporous polysaccharide powders |
Arista |
Powder |
Contact-independent application in selected procedures |
| Collagen products |
Various manufacturers |
Pad, sponge, patch |
Compete for surface bleeding and tissue support |
| Electrosurgical devices |
Multiple manufacturers |
Energy-based |
Can reduce use of topical hemostatic agents in selected cases |
TachoSil’s strongest commercial differentiator is the combination of a patch format and fibrin-based biological adhesion. Its main disadvantage is cost relative to some commodity mechanical agents.
What is the FDA regulatory status of TachoSil?
TachoSil is regulated as a biologically derived surgical hemostatic product. The U.S. product contains human fibrinogen and human thrombin on a collagen carrier. FDA labeling identifies its use as an adjunct to hemostasis when control by conventional surgical techniques is ineffective or impractical. [3]
The regulatory profile creates manufacturing and quality requirements that are more demanding than those for a simple absorbable surgical sponge. Relevant controls include:
- Human plasma sourcing and donor screening
- Viral safety and pathogen-reduction controls
- Fibrinogen and thrombin potency
- Collagen carrier specifications
- Sterility and stability
- Batch consistency
- Combination-product quality systems
TachoSil is not a conventional oral or injectable small-molecule product. Its regulatory pathway and product presentation reduce the likelihood of a simple generic copy.
What is the Orange Book status of TachoSil?
TachoSil does not function as a conventional Orange Book-listed prescription drug with a standard small-molecule patent-and-exclusivity profile. The product is a biologically derived surgical hemostatic patch and is not typically analyzed through the same Abbreviated New Drug Application framework used for tablets, capsules and many injectable drugs.
The commercial implications are significant:
- Orange Book patent listings are not the central source of market protection.
- A Paragraph IV challenge is not the expected primary route for competing entry.
- A substitute product would generally require its own regulatory authorization and evidence package.
- Competitive entry is more likely through a different fibrin sealant, patch, matrix, powder or device than through an identical “generic TachoSil.”
Are there Paragraph IV challenges or biosimilar risks for TachoSil?
No prominent public Paragraph IV litigation involving TachoSil has established a conventional generic-entry threat. The product’s biological ingredients, collagen carrier and patch presentation make a direct ANDA-style challenge less likely than substitution by an independently developed hemostatic product.
TachoSil also has limited conventional biosimilar risk. A competitor could develop a biologically similar fibrinogen-thrombin product, but commercial substitution would require more than matching the active proteins. The competitor would need to demonstrate appropriate quality, manufacturing controls, safety, performance and clinical usability for the delivery system.
The more credible risk is therapeutic substitution. Hospitals can select another FDA-authorized or otherwise jurisdictionally approved hemostatic product without reproducing the TachoSil formulation.
What patents protect TachoSil?
TachoSil’s product protection is likely to have been based on a combination of:
- Fibrinogen and thrombin compositions
- Coating methods for collagen sponges
- Drying and stabilization processes
- Patch structure and tissue-contact performance
- Packaging and storage methods
- Manufacturing controls
- Know-how related to biological sourcing and formulation
Public commercial materials do not provide a complete, current patent family analysis for TachoSil. The principal risk is that broad composition patents covering fibrinogen, thrombin or collagen are unlikely to provide durable exclusivity because those materials are well established. Any remaining defensible intellectual property would be more likely to reside in manufacturing process claims, product architecture, quality control and trade secrets.
How strong is the TachoSil patent estate?
The estate should be viewed as moderate for product replication and weaker for broad market exclusion.
| Protection layer |
Relative strength |
Reason |
| Fibrinogen composition |
Low to moderate |
Established biological material |
| Thrombin composition |
Low to moderate |
Established biological material |
| Collagen carrier |
Moderate |
Product-specific use and processing may matter |
| Patch architecture |
Moderate |
May create design-around opportunities |
| Manufacturing process |
Moderate to strong |
Process know-how can be difficult to reproduce |
| Plasma sourcing and viral safety |
Strong operational barrier |
Requires qualified supply and validated controls |
| Broad market exclusivity |
Low |
Several alternative hemostatic technologies exist |
The absence of a direct generic does not mean TachoSil has permanent exclusivity. Its protection is primarily a combination of regulatory complexity, manufacturing capability, clinical familiarity and hospital purchasing position.
What patent litigation and settlement activity affect TachoSil?
No major, publicly established U.S. patent litigation campaign has made TachoSil a central target comparable to leading small-molecule medicines. The commercial dispute risk is more likely to involve product liability, procurement, regulatory compliance, manufacturing quality or competition among surgical-hemostasis products.
No widely reported settlement agreement has created a defined generic-entry date for TachoSil. The lack of a Paragraph IV settlement framework reduces the usefulness of traditional patent-cliff analysis.
When does TachoSil lose exclusivity?
TachoSil does not have a single, publicly determinable loss-of-exclusivity date. Several forms of protection may expire at different times:
| Exclusivity type |
TachoSil position |
| Small-molecule patent exclusivity |
Not applicable |
| Standard Orange Book patent cliff |
Not the primary framework |
| Biologic reference-product exclusivity |
Not readily applicable in the same way as a monoclonal antibody |
| Formulation and manufacturing patents |
May vary by jurisdiction and family |
| Regulatory exclusivity |
Depends on the specific authorization and jurisdiction |
| Commercial exclusivity |
Continues only while clinical preference, supply reliability and pricing remain competitive |
The practical “loss of exclusivity” event would be the launch of a clinically accepted competing patch or a substantial shift in hospital purchasing. That event is market-driven rather than tied to one patent expiration date.
What manufacturing barriers protect TachoSil?
Manufacturing is one of the most important barriers to entry. A competing manufacturer must control a product that combines human plasma-derived proteins with an absorbable collagen carrier.
Key barriers include:
- Reliable supply of qualified human plasma
- Donor screening and infectious-disease testing
- Protein purification
- Viral inactivation or removal
- Consistent fibrinogen and thrombin activity
- Uniform coating of the collagen matrix
- Low-moisture packaging
- Shelf-life validation
- Sterility assurance
- Regulatory comparability and clinical validation
These barriers support pricing and reduce the probability of rapid low-cost imitation. They do not eliminate competition from products based on different mechanisms.
What generic launch scenarios exist for TachoSil?
Scenario 1: No direct generic launch
This is the most likely scenario. TachoSil remains a branded or specialty surgical product, while hospitals choose among competing hemostatic categories.
Scenario 2: Competing fibrin patch
A rival launches a fibrin-coated patch with similar handling and clinical use. This would create the greatest direct pricing pressure and could force contracting concessions.
Scenario 3: Hospital conversion to lower-cost agents
Hospitals replace TachoSil with oxidized cellulose, gelatin matrix, powders or liquid fibrin sealants in selected procedures. This scenario would reduce volume without requiring a legally defined generic launch.
Scenario 4: Portfolio-led defense by Corza
Corza uses bundled contracting, surgeon education and portfolio sales to retain TachoSil alongside other surgical products. This strategy could protect account access even if individual-product price pressure rises.
How does TachoSil compare with competing fibrin sealants?
TachoSil is differentiated by its patch format. Liquid products such as Tisseel and Vistaseal can cover irregular or larger surfaces, while TachoSil offers a preformed matrix that can be placed directly over a bleeding site.
| Attribute |
TachoSil |
Liquid fibrin sealant |
| Application |
Preformed patch |
Spray, drip or syringe |
| Handling |
Ready to apply |
Requires delivery-device handling |
| Irregular surfaces |
Less flexible |
More adaptable |
| Localized focal bleeding |
Strong fit |
Strong fit |
| Broad-area coverage |
More limited by patch size |
Often more flexible |
| Manufacturing complexity |
High |
High |
| Direct generic risk |
Low |
Low to moderate, depending on product |
TachoSil’s commercial position is strongest when operating-room speed, patch handling and localized tissue coverage outweigh the price premium.
What is the investment and licensing outlook?
TachoSil is more relevant to specialty surgical-product investors and strategics than to traditional pharmaceutical investors seeking a high-growth biologic franchise.
Potential strategic value comes from:
- Recurring procedure-linked demand
- Established surgeon familiarity
- Complementarity with other hemostatic products
- Manufacturing barriers
- Expansion through international distribution
- Cross-selling within Corza’s surgical portfolio
The principal limitations are the lack of public product-level financial reporting, exposure to hospital procurement budgets, and competition from multiple alternative technologies.
A licensing or acquisition analysis should focus on contribution margin, hospital contract retention, procedure mix, manufacturing capacity, plasma supply, regulatory commitments and the durability of surgeon preference. Revenue alone would not provide a sufficient valuation basis.
Key Takeaways
- TachoSil is a human fibrinogen and thrombin-coated collagen patch for surgical hemostasis.
- Takeda sold the product to Corza Medical in 2021.
- Neither Takeda nor Corza publicly reports a complete standalone TachoSil revenue series.
- TachoSil has no conventional small-molecule patent cliff or clearly defined Paragraph IV launch date.
- Direct biosimilar and generic risk is limited, but therapeutic substitution risk is material.
- Manufacturing, plasma sourcing, quality systems and clinical familiarity are major barriers to entry.
- The main competitors are fibrin sealants, fibrin patches, oxidized cellulose, gelatin matrices, powders and electrosurgical devices.
- Financial performance is most sensitive to surgical volume, hospital formulary status, pricing and competitive conversion.
- The patent estate is likely more important for formulation, patch construction and manufacturing than for broad active-ingredient exclusivity.
- TachoSil is best analyzed as a specialty surgical-hemostasis franchise, not as a conventional biologic drug with a single loss-of-exclusivity date.
FAQs
Is TachoSil a biologic drug or a medical device?
TachoSil is a biologically derived surgical hemostatic product delivered as a patch. Its regulatory classification differs by jurisdiction, but it is not comparable to a conventional oral drug or monoclonal antibody.
Does TachoSil have a biosimilar competitor?
No widely established biosimilar competitor has created a material market event for TachoSil. Competition is more likely to arise from independently authorized fibrin sealants and other topical hemostats.
Is TachoSil listed in the FDA Orange Book?
TachoSil is not generally analyzed through the standard Orange Book framework used for conventional prescription drugs. Its market protection depends more on regulatory complexity, manufacturing capabilities and clinical substitution barriers.
Who manufactures TachoSil now?
TachoSil is associated with Corza Medical following Takeda’s divestiture of the product. Manufacturing and distribution arrangements can vary by market and should be distinguished from the commercial brand owner.
What is the main threat to TachoSil sales?
The main threat is substitution by competing surgical-hemostasis products, particularly lower-cost mechanical agents, flowable matrices, liquid fibrin sealants and alternative patches.
References
-
Takeda Pharmaceutical Company Limited. (2021). Annual report 2021 and disclosures regarding the divestiture of TachoSil. Takeda Pharmaceutical Company Limited.
-
Corza Medical. (2021). Corza Medical completes acquisition of TachoSil from Takeda. Corza Medical.
-
U.S. Food and Drug Administration. (2010). TachoSil fibrin sealant patch: Prescribing information and product labeling. FDA.